• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

West Pharmaceutial Services beats The Street, raises guidance

July 29, 2021 By Sean Whooley

West Pharmaceutical Services - updated logoWest Pharmaceutical Services (NYSE:WST) shares ticked up before hours on second-quarter results that beat the consensus forecast.

The Exton, Pa.-based company posted profits of $187.3 million, or $2.47 per share, on sales of $723.6 million for the three months ended June 30, 2021, more than doubling its bottom-line on sales growth of 37.3%.

Adjusted to exclude one-time items, earnings per share were $2.46, 72¢ ahead of Wall Street, where analysts were looking for sales of $669.4 million.

“Our strong second-quarter performance was driven by continued momentum in organic sales growth in both our base business as well as increased demand for our products associated with COVID-19 vaccines,” West Pharmaceutical Services president & CEO Eric M. Green said in a news release.  “Our market-led strategy coupled with our scientific leadership and regulatory insights in primary packaging and delivery of injectable drugs have resonated with our customers, resulting in a high participation rate on newly approved molecular entities, especially large molecule therapies. Over the past year and a half, we have accelerated capital spending and expanded global [high-value product] manufacturing capacity.

“Based on growing future demand from our customers, we are announcing another tranche of capital spending to expand HVP capacity that we expect will be ready for production in 2022.  Given the strong first half of the year, we are raising our full-year financial guidance.”

West Pharmaceutical Services said it now expects to log full-year adjusted EPS of between $8.05 and $8.20, compared with a range of $6.95 to $7.10 previously. The company raised its sales guidance for between $2.76 billion and $2.785 billion, having previously set projections at a range of $2.63 billion to $2.655 billion.

WST shares were up 1.3% at $388.83 per share in pre-market trading.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: West Pharmaceutical, West Pharmaceutical Services

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS